Post Marketing Surveillance to Observe Safety of Prevenar 13 in Adults

Trial Profile

Post Marketing Surveillance to Observe Safety of Prevenar 13 in Adults

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 20 Jul 2016 Status changed from recruiting to completed.
    • 14 Feb 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 14 Jun 2013 Planned initiation date changed from 1 May 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top